DiaMedica Q1 Net, Operating Income Miss Estimates; ReMEDy2 Stroke Trial Nears Key Interim Analysis
DMAC sits 88% above its 52-week low of $3.475.
Summary
DiaMedica Therapeutics reported a Q1 net income miss of $10.04 million against estimates of $9.53 million, and an operating income miss of $10.48 million against $9.86 million, though adjusted EPS met expectations. Despite these financial misses, the company ended the quarter with a strong cash position of $51.3 million, providing a projected runway through 2027. Critically, its ReMEDy2 stroke trial has surpassed 70% enrollment, with a significant interim analysis planned for the fourth quarter of 2026. The anticipated moderate increase in R&D expenses is directly tied to the advancement and global expansion of this and other clinical programs. Traders will be watching for the results of the ReMEDy2 interim analysis as a major catalyst for the stock.
At the time of this announcement, DMAC was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $351.3M. The 52-week trading range was $3.48 to $10.42. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.